Who owns Rapport Therapeutics, Inc., from the filings themselves: stakes over 5% (Schedule 13D/G), the institutional managers reporting the stock each quarter (13F), and the funds holding it (N-PORT).
Investors crossing 5% ownership must disclose it. Schedule 13G filers certify the stake is passive; Schedule 13D is the general form for everyone else — founders, strategic holders, and activists alike. Each entry is the holder's most recent disclosure. Coverage begins with SEC's structured filings from December 18, 2024; a holder appears once they file or amend after that date.
Third Rock Ventures V, L.P.: 13.1% · 6,280,525 shares — Third Rock Ventures GP V, L.P.: 13.1% · 6,280,525 shares — TRV GP V, LLC: 13.1% · 6,280,525 shares
Cormorant Asset Management, LP: 5.6% · 2,657,521 shares — Bihua Chen: 5.6% · 2,657,521 shares
4 more 5% stakes behind a free account
See every investor who has disclosed crossing 5% of Rapport Therapeutics, Inc..
Sign up freeEvery institutional manager whose latest 13F reports this stock, largest position first. "% of their portfolio" is the weight inside that manager's own book — how much conviction the position represents; "% of company" is how much of Rapport Therapeutics, Inc. they hold. Together these 193 managers report 111.61% of shares outstanding.
| Investor | Position value | Shares | % of their portfolio | % of company | As of |
|---|---|---|---|---|---|
| FMR LLC | $299M | 7,172,894 | 0.01% | 14.95% | June 30, 2026 |
| TRV GP V, LLC | $262M | 6,280,525 | 52.53% | 13.09% | June 30, 2026 |
191 more institutional holders behind a free account
See every manager reporting Rapport Therapeutics, Inc., how much of the company they hold, and how big the position is inside their own portfolio.
Sign up freeFunds disclosing this stock in their monthly N-PORT portfolio, with the position's share of the fund's net assets. Together these 179 funds hold 29.94% of shares outstanding — counted inside the manager totals above, not on top of them, since a fund's shares also appear in its manager's 13F.
| Fund | Position value | % of net assets | % of company | As of |
|---|---|---|---|---|
| SMALLCAP World Fund Inc | $141M | 0.15% | 7.07% | June 30, 2026 |
| Fidelity Growth Company Fund | $57.9M | 0.07% | 4.16% | February 28, 2026 |
177 more funds behind a free account
See every fund holding Rapport Therapeutics, Inc. and what share of its net assets the position represents.
Sign up freeLoading...
